Clinical Trials Logo

Hyperuricemia clinical trials

View clinical trials related to Hyperuricemia.

Filter by:

NCT ID: NCT03372200 Completed - Clinical trials for Hyperuricemia With or Without Gout

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: January 9, 2018
Phase: Phase 3
Study type: Interventional

FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

NCT ID: NCT03316131 Completed - Clinical trials for Asymptomatic Hyperuricemia

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Start date: October 25, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit

NCT ID: NCT03306758 Not yet recruiting - Gout Clinical Trials

The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This study evaluate the serum uric acid lowering effect of sodium bicarbonate as well as its safety in patients with asymptomatic hyperuricemia or gout. Half of the participants will receive sodium bicarbonate only, while the other half receive none.

NCT ID: NCT03218709 Recruiting - Hyperuricemia Clinical Trials

The Intervention of Multi-vitamin With Minerals to Hyperuricemia

Start date: January 2017
Phase: Phase 4
Study type: Interventional

To evaluate the validity of multi-vitamin-and-minerals intervention on uric acid metabolism in hyperuricemic adults.

NCT ID: NCT03211403 Completed - Gout Clinical Trials

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

Start date: July 4, 2017
Phase: Phase 1
Study type: Interventional

This is a single-Center, randomized, double-Blind, placebo-controlled, multiple ascending-dose Phase I trail.

NCT ID: NCT03200210 Recruiting - Hyperuricemia Clinical Trials

Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients

LUMINA
Start date: July 11, 2017
Phase: Phase 4
Study type: Interventional

The investigators will enroll continuous ambulatory peritoneal dialysis (CAPD) patients with hyperuricemia and randomly divide them into two groups, treated with Febuxostat and placebo respectively. After 3 years of following up, cardiovascular events, all cause mortality, cardiovascular mortality and non-fatal cardiovascular events are collected and recorded. The difference of cardiovascular events, all cause mortality and non-fatal cardiovascular event rate will be analyzed.

NCT ID: NCT03185793 Completed - Hyperuricemia Clinical Trials

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Start date: July 20, 2017
Phase: Phase 2
Study type: Interventional

The objective of the study is to assess efficacy and safety of SHR4640 in subjects with hyperuricemia.

NCT ID: NCT03149939 Completed - Hyperuricemia Clinical Trials

Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

NCT ID: NCT03118739 Completed - Type 2 Diabetes Clinical Trials

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Start date: May 18, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).

NCT ID: NCT03100318 Completed - Clinical trials for Hyperuricemia With or Without Gout

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: April 1, 2017
Phase: Phase 3
Study type: Interventional

FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.